Adam Maeder
Stock Analyst at Piper Sandler
(3.47)
# 941
Out of 5,006 analysts
94
Total ratings
47.62%
Success rate
6.6%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RBOT Vicarious Surgical | Maintains: Neutral | $8.5 → $7 | $6.91 | +1.30% | 8 | Aug 13, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $233 → $150 | $76.37 | +96.41% | 15 | Aug 5, 2025 | |
| RMD ResMed | Maintains: Neutral | $248 → $270 | $281.38 | -4.04% | 4 | Aug 1, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $83 → $90 | $76.56 | +17.55% | 16 | Jul 25, 2025 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $575 → $595 | $449.69 | +32.31% | 20 | Jul 23, 2025 | |
| RXST RxSight | Maintains: Neutral | $18 → $10 | $8.49 | +17.79% | 2 | Jul 9, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $3.5 → $4 | $3.36 | +19.05% | 1 | Jun 18, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $2.50 | +60.00% | 4 | May 12, 2025 | |
| TCMD Tactile Systems Technology | Downgrades: Neutral | $25 → $14 | $15.17 | -7.71% | 3 | May 6, 2025 | |
| ABT Abbott Laboratories | Reiterates: Overweight | $133 → $145 | $133.74 | +8.42% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $18.30 | +14.75% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $2.83 | +182.69% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $5.80 | +244.83% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $3.30 | +51.52% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $1.47 | +1,124.49% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $52.63 | +88.11% | 3 | May 5, 2022 |
Vicarious Surgical
Aug 13, 2025
Maintains: Neutral
Price Target: $8.5 → $7
Current: $6.91
Upside: +1.30%
Inspire Medical Systems
Aug 5, 2025
Maintains: Overweight
Price Target: $233 → $150
Current: $76.37
Upside: +96.41%
ResMed
Aug 1, 2025
Maintains: Neutral
Price Target: $248 → $270
Current: $281.38
Upside: -4.04%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $83 → $90
Current: $76.56
Upside: +17.55%
Intuitive Surgical
Jul 23, 2025
Reiterates: Overweight
Price Target: $575 → $595
Current: $449.69
Upside: +32.31%
RxSight
Jul 9, 2025
Maintains: Neutral
Price Target: $18 → $10
Current: $8.49
Upside: +17.79%
Sight Sciences
Jun 18, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $3.36
Upside: +19.05%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $2.50
Upside: +60.00%
Tactile Systems Technology
May 6, 2025
Downgrades: Neutral
Price Target: $25 → $14
Current: $15.17
Upside: -7.71%
Abbott Laboratories
Apr 17, 2025
Reiterates: Overweight
Price Target: $133 → $145
Current: $133.74
Upside: +8.42%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $18.30
Upside: +14.75%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $2.83
Upside: +182.69%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $5.80
Upside: +244.83%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $3.30
Upside: +51.52%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $1.47
Upside: +1,124.49%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $52.63
Upside: +88.11%